Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis
G Garcia–Tsao - Gastroenterology, 2001 - Elsevier
Portal hypertension is the main complication of cir-rhosis because it is directly responsible
for two of its most common and potentially lethal complications: variceal hemorrhage and …
for two of its most common and potentially lethal complications: variceal hemorrhage and …
Renin–angiotensin–aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis
BACKGROUND & AIMS: Renin–angiotensin–aldosterone antagonists [ACE inhibitors
(ACEi), angiotensin receptor blockers (ARB), aldosterone antagonists (AA)] are potential …
(ACEi), angiotensin receptor blockers (ARB), aldosterone antagonists (AA)] are potential …
Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis
AW Schneider, JF Kalk, CP Klein - Hepatology, 1999 - Wiley Online Library
Administration of angiotensin II causes an increase in portal pressure, and plasma
concentration of angiotensin II is elevated in patients with cirrhosis, suggesting that …
concentration of angiotensin II is elevated in patients with cirrhosis, suggesting that …
Pathways of hepatic and renal damage through non‐classical activation of the renin‐angiotensin system in chronic liver disease
G Sansoè, M Aragno, F Wong - Liver International, 2020 - Wiley Online Library
In liver cirrhosis, renin‐angiotensin system (RAS) activation sustains renal sodium retention
and hepatic fibrogenesis. New information has recently enlivened the traditional concept of …
and hepatic fibrogenesis. New information has recently enlivened the traditional concept of …
End-organ dysfunction in cystic fibrosis: association with angiotensin I converting enzyme and cytokine gene polymorphisms
PD Arkwright, V Pravica, PJ Geraghty… - American journal of …, 2003 - atsjournals.org
The clinical course of patients with cystic fibrosis (CF) with functionally similar mutations in
the CF transmembrane conductance regulator gene is variable and must therefore relate to …
the CF transmembrane conductance regulator gene is variable and must therefore relate to …
Impact of inhibitors of the Renin-Angiotensin-aldosterone system on liver fibrosis and portal hypertension
U Tox, HM Steffen - Current medicinal chemistry, 2006 - ingentaconnect.com
Morbidity and mortality of chronic liver disease are primarily caused by liver cirrhosis and
portal hypertension, both of them secondary disorders of progressive liver fibrosis. The main …
portal hypertension, both of them secondary disorders of progressive liver fibrosis. The main …
Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity
Background The effect of an angiotensin II blockade in lowering the portal pressure in
patients with liver cirrhosis and portal hypertension is controversial. This prospective study …
patients with liver cirrhosis and portal hypertension is controversial. This prospective study …
Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease
J Vlachogiannakos, AKW Tang, D Patch, AK Burroughs - Gut, 2001 - gut.bmj.com
Gut: first published as 10.1136/gut. 49.2. 303 on 1 August 2001. Downloaded from of
ascites, salt restriction, use of diuretics, and renal function impairment) it is diYcult to make …
ascites, salt restriction, use of diuretics, and renal function impairment) it is diYcult to make …
Pharmacological treatment of portal hypertension: hemodynamic effects and prevention of bleeding
D Lebrec - Pharmacology & therapeutics, 1994 - Elsevier
In the past 10 yeats, it has been clearly shown that vasoactive substances reduce portal
pressure in patients or animals with portal hypertension. Some of these substances act by …
pressure in patients or animals with portal hypertension. Some of these substances act by …
Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension
W Debernardi-Venon, C Barletti, C Alessandria… - Digestive diseases and …, 2002 - Springer
The use of angiotensin II antagonists in the treatment of portal hypertension remains
controversial. Our aims were to assess the effect of Irbesartan on portal pressure and to …
controversial. Our aims were to assess the effect of Irbesartan on portal pressure and to …